ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Performance Characteristics of an Analytic Model Predicting Retroperitoneal Lymph Node Dissection Pathology Following First-Line Chemotherapy for Patients With Metastatic Nonseminomatous Germ Cell Tumors.The Journal of urology · 2025Article
- Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Article
- Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project.Nature communications · 2024Article
- Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer.Journal of clinical medicine · 2024Article
- Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages.Cancers · 2023Article
- Alpha-fetoprotein-elevated postpubertal testicular teratoma with retroperitoneal metastasis onFrontiers in medicine · 2023Article
- Article
- Article
- Teratomatous Elements in Orchiectomy Specimens Are Associated with a Reduced Relapse-Free Survival in Metastasized Testicular Germ Cell Tumors.Urologia internationalis · 2022Article
- Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.The oncologist · 2021Article
- The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles.Marine drugs · 2021Review
- Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy.The Annals of thoracic surgery · 2021Article
- Article
- Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.Cancers · 2020Article
- Article
- Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- MicroRNAs in Differentiation of Embryoid Bodies and the Teratoma Subtype of Testicular Cancer.Cancer genomics & proteomicsArticle
- 23-Year-Old Male with Testis Cancer with Spontaneous Ruptured Teratocarcinoma and No History of Trauma: A Case Report.Case reports in oncologyArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 8 institutions in 10 countries.
Funding
Abstract
purposeIn men with metastatic germ cell tumors (GCTs), risk-directed treatment is determined, in part, by a distinction between seminoma and nonseminomatous GCT (NSGCT). The importance of NSGCT cell type is uncertain. We evaluated the long-term impact of teratoma on survival in patients with NSGCT.
methodsPrechemotherapy, primary tumors from patients who received platinum-based chemotherapy were studied, and the histology was confirmed by a genitourinary pathologist. The cumulative incidence of disease-related death (CIDD) was the primary end point, and a competing-risk analysis was performed.
resultsTumors were available from 232 patients, including 193 with NSGCT. An element of teratoma was present in 82 NSGCT primary tumors (42%). With a median follow-up of 17 years (range, 0.3 to 35 years), 58 patients with NSGCT died, 47 as a result of GCT and 11 as a result of other causes. Most GCT deaths occurred within the first 5 years and were associated with pretreatment risk status (
conclusionThe presence of teratoma, particularly mature teratoma, in an NSGCT primary tumor is associated with a higher CIDD, consistent with the hypothesis that differentiation is associated with adverse outcomes. Death as a result of non-GCT causes is not associated with risk status and must be separated from GCT death when evaluating long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.